KMT2A

Histone-lysine N-methyltransferase 2A · Q03164 · KMT2A on Sugi Atlas →

7,363,712 patent compounds predicted against KMT2A, 3,595,204 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Reserpine (SCHEMBL2589)	1.00	13/20
Daunorubicin (SCHEMBL3041)	1.00	10/20
Chlortetracycline (SCHEMBL3841)	0.71	10/20
Chlortetracycline (SCHEMBL3842)	0.71	10/20
Demeclocycline (SCHEMBL3252)	0.71	10/20
Demeclocycline (SCHEMBL3253)	0.71	10/20
Chlortetracycline (SCHEMBL3110)	0.70	10/20
Chlortetracycline (SCHEMBL3111)	0.70	10/20
Epirubicin (SCHEMBL3165)	1.00	9/20
Doxorubicin (SCHEMBL3242)	1.00	9/20
Doxorubicin (SCHEMBL3243)	1.00	9/20
Idarubicin (SCHEMBL3750)	1.00	9/20
Phenazopyridine (SCHEMBL270)	0.77	9/20
Oxytetracycline (SCHEMBL2898)	0.70	9/20
Oxytetracycline (SCHEMBL2899)	0.70	9/20
SCHEMBL3446	0.62	9/20
Meclocycline (SCHEMBL3445)	0.59	9/20
Iodoquinol (SCHEMBL3460)	1.00	8/20
Esorubicin (SCHEMBL3864)	0.81	8/20
Tetracycline (SCHEMBL3098)	0.70	8/20

Clinical trials — most relevant to KMT2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML	PHASE3	RECRUITING
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients	PHASE3	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia	PHASE2	RECRUITING
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	PHASE2	COMPLETED
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation	PHASE1/PHASE2	RECRUITING
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors	PHASE2	RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML	PHASE2	NOT_YET_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Revumenib and Mezigdomide in People With Leukemia	PHASE1/PHASE2	RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment	PHASE2	NOT_YET_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias	PHASE1	WITHDRAWN
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia	PHASE1	NOT_YET_RECRUITING
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias	PHASE1	RECRUITING
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant	PHASE1	RECRUITING
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML	PHASE1	NOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Expanded Access Program for Revumenib	nan	NO_LONGER_AVAILABLE
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Expanded Access to Ziftomenib	nan	AVAILABLE
Mechanisms of Immune Deficiency	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KMT2A binder may also engage these)

Protein	Name	Similarity
P55200	—	1.000	P55200 →
D6RIA3	—	0.994	D6RIA3 →
Q9P1Y6	—	0.992	Q9P1Y6 →
Q8CH77	—	0.992	Q8CH77 →
Q5TZ18	—	0.992	Q5TZ18 →
Q9VT00	—	0.992	Q9VT00 →
Q9Y2X9	—	0.991	Q9Y2X9 →
Q66J90	—	0.991	Q66J90 →
P20659	—	0.991	P20659 →
Q9VYD1	—	0.991	Q9VYD1 →
A6H619	—	0.991	A6H619 →
Q80TN7	—	0.991	Q80TN7 →
Q8BZ32	—	0.991	Q8BZ32 →
B3MLB7	—	0.990	B3MLB7 →
Q5T1R4	—	0.990	Q5T1R4 →
Q8NEY1	—	0.990	Q8NEY1 →
Q86TC9	—	0.990	Q86TC9 →
B0QZF7	—	0.990	B0QZF7 →
Q9VQI9	—	0.990	Q9VQI9 →
Q3T0A6	—	0.990	Q3T0A6 →
ASH1L	Histone-lysine N-methyltransferase ASH1L	0.990	landscape →
Q9JIX8	—	0.989	Q9JIX8 →
Q6KCD5	—	0.989	Q6KCD5 →
CBX6	Chromobox protein homolog 6	0.989	landscape →
F1QIC4	—	0.989	F1QIC4 →
KDM3B	Lysine-specific demethylase 3B	0.989	landscape →
P70047	—	0.989	P70047 →
Q9VW15	—	0.989	Q9VW15 →
Q03172	—	0.989	Q03172 →
TET3	Methylcytosine dioxygenase TET3	0.989	landscape →